Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Other financing activities (2016 - 2018)

Aptevo Therapeutics (APVO) has disclosed Other financing activities for 3 consecutive years, with $601000.0 as the latest value for Q3 2018.

  • Quarterly Other financing activities rose 191.2% to $601000.0 in Q3 2018 from the year-ago period, while the trailing twelve-month figure was -$10.2 million through Sep 2018, down 506.21% year-over-year, with the annual reading at -$10.0 million for FY2017, 609.68% down from the prior year.
  • Other financing activities hit $601000.0 in Q3 2018 for Aptevo Therapeutics, up from -$10.2 million in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $2.4 million in Q4 2016 to a low of -$10.2 million in Q4 2017.
  • Historically, Other financing activities has averaged -$1.2 million across 3 years, with a median of $302500.0 in 2017.
  • Biggest five-year swings in Other financing activities: crashed 529.72% in 2017 and later soared 191.2% in 2018.
  • Year by year, Other financing activities stood at $2.4 million in 2016, then plummeted by 529.72% to -$10.2 million in 2017, then surged by 105.92% to $601000.0 in 2018.
  • Business Quant data shows Other financing activities for APVO at $601000.0 in Q3 2018, -$10.2 million in Q4 2017, and -$659000.0 in Q3 2017.